Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033196 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab in Lung Transplantation
A Phase 2 study of Lung Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06033196 is a Phase 2 study of Lung Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 350 participants, below the 1,253-participant average among 15 other Lung Transplant trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06033196, a Phase 2 study of Lung Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG Placebo for Tocilizumab
Study Locations (20)
Texas
- University of Texas Southwestern (Site #: 71187) - Dallas
- Houston Methodist Hospital (Site #: 71120) - Houston
- University of Texas Health Science at San Antonio (Site #: 71198) - San Antonio
California
- Cedars Sinai Medical Center (Site #: 71146) - Beverly Hills
- David Geffen School of Medicine at UCLA (Site #: 71123) - Los Angeles
Massachusetts
- Massachusetts General Hospital (Site #: 71107) - Boston
- Boston Children's Hospital and Harvard Medical School (Site #: 71001) - Boston
Missouri
- Barnes Jewish Hospital/ Washington University SOM (Site #: 71191) - St Louis
- St. Louis Children's Hospital of Washington University (Site #: 71006) - St Louis
Ohio
- Cleveland Clinic (Site #: 71101) - Cleveland
- Ohio State University Medical Center (Site #: 71196) - Columbus
Arizona
- St. Joseph's Hospital and Medical Center (Site #: 71192) - Phoenix
Florida
- University of Florida Shands Hospital (Site #: 71131) - Gainesville
Georgia
- Emory University (Site #: 71103) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2029-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033196
The ClinicalTrials.gov registry entry for NCT06033196 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,253-participant average among 15 other Lung Transplant trials with a reported enrollment target (72% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT06033196 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06033196 about?
NCT06033196 is a clinical study titled "Tocilizumab in Lung Transplantation". This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycop...
What is the current status of trial NCT06033196?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-02-13. Estimated completion is 2029-01-08.
What conditions does trial NCT06033196 study?
This clinical trial studies the following conditions: Lung Transplant.
What interventions are being tested in trial NCT06033196?
The interventions under investigation include: Tocilizumab (DRUG), Placebo for Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06033196?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033196 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
RECRUITING · Phase 2
-
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
RECRUITING
-
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
RECRUITING · NA
-
Planned Semi-Elective Lung Tx Study
RECRUITING · NA
-
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
RECRUITING
-
A Study of Latin Dance for Post- Lung Transplant
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.